Overview highlights role of dental practitioners in managing patients on bone-modifying agents, indicating clinical relevance of MRONJ.
Medication-related osteonecrosis of the jaw (MRONJ) remains a prevalent risk in the dental setting, owing to the increasing number of conditions treated with bone-modifying agents, as well as the evolving list of medications attributed to this condition. This two-part series will provide an overview of MRONJ and its management. Part 1 provides a background on MRONJ, as well as discussing the role of the general dental practitioner in managing patients who are planned for bone-modifying agents. Part 2 will discuss the management of patients with MRONJ. CPD/Clinical Relevance: Clinicians should be aware of medication-related osteonecrosis of the jaw.
No takes yet. Share an insight, caveat, or question.
Arya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: